CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET ANALYSIS

Key Developments

• In April 2023, Bioiberica S.A.U., a global life science company, launched a new retail product to address atopic dermatitis in dogs and cats. The product is a collar that contains the company’s lipids-based Biosfeen ingredient for atopic dermatitis. Biosfeen is a sphingolipids ingredient that is said to increase filaggrin expression. Filaggrin plays a role in the skin’s barrier function.
• In January 2023, Royal Canin North America, a global leader in pet health nutrition, announced the launch of SKINTOPIC, a new diet for the management of canine atopic dermatitis, a chronic pruritic skin disease in which dogs are hypersensitive to environmental allergens
• In January 2023, Animal Dermatology Group, Inc (ADG), a U.S.-based, privately-owned, veterinary dermatology specialty company, acquired Animal Skin and Allergy Clinic of Washington, U.S. displaying the company’s goals to further an aggressive pace of expansion in 2023. Animal Skin and Allergy Clinic (ASAC) has provided veterinary dermatology services to pets in the northern Washington and Seattle metropolitan area for over 30 years.
• In July 2021, Virbac, an animal health pharmaceutical company, launched Cyclavance, the first U.S. Food and drug Administration approved liquid cyclosporine for dogs diagnosed with atopic dermatitis. Cyclavance (cyclosporine oral solution) is a substitute for Atopica cyclosporine pills made by Elanco Animal Health, a global leader in animal health. In dogs weighing at least 4 pounds, the new Virbac prescription medication is authorized for the treatment of atopic dermatitis.